Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary HypertensionStatus: open
A Multicenter, Randomized, Double-blinded, Placebo- Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
Treatment for Pulmonary Arterial Hypertension
This is a multicenter, randomized (1:1 inhaled treprostinil: placebo), double-blinded, placebo-controlled trial to evaluate the safety and efficacy of inhaled treprostinil in subjects with pre-capillary pulmonary hypertension (PH) associated with interstitial lung disease (ILD) including combined pulmonary fibrosis and emphysema (CPFE). The study will include about 314 patients at approximately 120 clinical trial centers. The treatment phase of the study will last approximately 16 weeks. Patients who complete all required assessments will also be eligible to enter an open-label, extension study (RIN-PH-202).
SponsorsThis trial is sponsored by United Therapeutics.
Interested in Clinical Trial?
Providers Associated With This Trial
- Karen A. Fagan, M.D.PulmonologistDirector of Division Pulmonary & Critical Care; Director of Pulmonary Hypertension Center; Associate Professor of Internal Medicine
- Philip Almalouf, M.D.PulmonologistAssistant Professor of Internal Medicine